Loading...
Please wait, while we are loading the content...
Similar Documents
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
| Content Provider | Europe PMC |
|---|---|
| Author | Zhou, Xiaofei Sedarati, Farhad Faller, Douglas V. Zhao, Dan Faessel, Hélène M. Chowdhury, Swapan Bolleddula, Jayaprakasam Li, Yuexian Venkatakrishnan, Karthik Papai, Zsuzsanna |
| Abstract | SummaryPevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase I trial characterizing the mass balance, pharmacokinetics, and clearance pathways of [14C]-pevonedistat in patients with advanced solid tumors (NCT03057366). In part A (n = 8), patients received a single 1-h intravenous infusion of [14C]-pevonedistat 25 mg/m2. In part B (n = 7), patients received pevonedistat 25 or 20 mg/m2 on days 1, 3, and 5 in combination with, respectively, docetaxel 75 mg/m2 or carboplatin AUC5 plus paclitaxel 175 mg/m2 on day 1 every 3 weeks. Following the single dose of [14C]-pevonedistat 25 mg/m2 in part A, there was a parallel log-linear decline in plasma and whole blood pevonedistat concentration, with systemic exposure of unchanged pevonedistat representing 41% of drug-related material (i.e., unchanged pevonedistat and its metabolites). The mean terminal half-life of pevonedistat and drug-related material in plasma was 8.4 and 15.6 h, respectively. Pevonedistat distributed preferentially in whole blood with a mean whole-blood-to-plasma ratio for pevonedistat AUC∞ of 40.8. By 1 week post dose, the mean recovery of administered radioactivity was 94% (41% in urine and 53% in feces). The pevonedistat safety profile during both study parts was consistent with previous clinical experience, with no new safety signals observed. In part B, pevonedistat in combination with docetaxel or carboplatin plus paclitaxel was generally well tolerated. ClinicalTrials.gov identifier: NCT03057366.Electronic supplementary materialThe online version of this article (10.1007/s10637-020-01017-x) contains supplementary material, which is available to authorized users. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7960626&blobtype=pdf |
| ISSN | 01676997 |
| Journal | Investigational New Drugs [Invest New Drugs] |
| Volume Number | 39 |
| DOI | 10.1007/s10637-020-01017-x |
| PubMed Central reference number | PMC7960626 |
| Issue Number | 2 |
| PubMed reference number | 33089874 |
| e-ISSN | 15730646 |
| Language | English |
| Publisher | Springer US |
| Publisher Date | 2020-10-22 |
| Publisher Place | New York |
| Access Restriction | Open |
| Rights License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2020 |
| Subject Keyword | pevonedistat advanced solid tumors phase I mass balance pharmacokinetics elimination |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology Pharmacology (medical) Oncology |
